Clinical Trials

8 enrolled

Colorectal Neoplasms

NCT04844385 2024-02-09

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

124 enrolled

Esophageal Squamous Cell Carcinoma

NCT05576961 2024-01-23

Safety and Efficacy of RX-af01 Combined With PD-1 Antibody

Phase EARLY_PHASE1 Unknown

60 enrolled

Other solid neoplasm

Solid Tumor

NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

40 enrolled

Thoracic

EGFR Positive Non-small Cell Lung Cancer

NCT04025931 2023-12-29

Chidamide Combined With Toripalimab in Sarcoma

74 enrolled

Sarcoma

NCT05580445 2023-11-22

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

114 enrolled

Advanced Pancreatic Cancer

NCT06081582 2023-10-13

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

33 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06078982 2023-10-12

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

39 enrolled

Stomach Neoplasms

NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

6 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT05994456 2023-08-16

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

24 enrolled

Stomach Neoplasms

NCT04135690 2023-08-15

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

60 enrolled

Carcinoma, Hepatocellular

NCT04653480 2023-07-17

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

61 enrolled

Colorectal Neoplasms

NCT05798533 2023-07-10

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

6 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05451407 2023-07-07

Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma

50 enrolled

Dermatologic

Melanoma

NCT05907512 2023-06-22

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

43 enrolled

Dermatologic

Melanoma

NCT05478473 2023-06-18

Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma

Phase NA Unknown

43 enrolled

Dermatologic

Melanoma

NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

30 enrolled

Thoracic

Non Small Cell Lung Cancer Recurrent

NCT05229315 2023-04-13

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

45 enrolled

Nasopharyngeal Carcinoma

NCT04172805 2023-04-12

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

70 enrolled

Sarcoma

NCT05803915 2023-04-07

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

57 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04667793 2023-04-04

Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor

15 enrolled

Thymic epithelial tumor

NCT04010071 2023-03-29

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

60 enrolled

Biliary Tract Neoplasms, Liver Neoplasms

NCT04211168 2023-03-29

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

44 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT04368078 2023-03-29

Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma

76 enrolled

Carcinoma, Hepatocellular

NCT05763927 2023-03-10

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

44 enrolled

Rectal Neoplasms

NCT05163483 2023-03-06

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

87 enrolled

Esophageal Squamous Cell Carcinoma

NCT05749575 2023-03-01

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

28 enrolled

Breast Neoplasms

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT04856631 2022-12-19

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

88 enrolled

Head and Neck Squamous Cell Cancer

NCT05350943 2022-10-18

HAIC Combined With Toripalimab and Donafenib for Advanced BTC

70 enrolled

Biliary Tract Adenocarcinoma

NCT03864211 2022-09-29

Thermal Ablation Followed by Immunotherapy for HCC

145 enrolled

Carcinoma, Hepatocellular

NCT05493332 2022-08-18

HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC

93 enrolled

Carcinoma, Hepatocellular

NCT05502393 2022-08-16

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

118 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05491694 2022-08-08

HIFU

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

1 enrolled

PD-1 Antibody

NCT05448183 2022-07-07

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

45 enrolled

Cholangiocarcinoma

NCT05420597 2022-06-15

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

61 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT05369286 2022-05-11

A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors

28 enrolled

Other solid neoplasm

Solid Tumor

NCT05162196 2022-05-02

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

57 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04073784 2022-04-26

Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

41 enrolled

Nasopharyngeal Carcinoma

NCT05341193 2022-04-22

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

32 enrolled

Nasopharyngeal Carcinoma

NCT05342506 2022-04-22

Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies

30 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms

NCT04058470 2022-04-14

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

140 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT04099589 2022-03-29

Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

64 enrolled

Genitourinary

Upper Tract Urinary Carcinoma

NCT05291910 2022-03-23

Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

Phase 4 Unknown

70 enrolled

Breast Neoplasms

NCT04119622 2022-03-11

Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer

30 enrolled

Stomach Neoplasms

NCT05173142 2022-03-08

HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors

141 enrolled

Stomach Neoplasms

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

138 enrolled

Breast Neoplasms

NCT05240404 2022-02-15

Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

116 enrolled

Carcinoma, Hepatocellular

NCT05233358 2022-02-10

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Phase NA Unknown

176 enrolled